CONTENTS

1  Partners – overview
3-5  Brighton Centre floorplans
6  Welcome address
7  Committees
8-13  Programme at a glance
14-20  Partners
22-25  Exhibitors
26-46  Programme
47  Clinigene Industry Satellite: joint platform between industry and centres of excellence
48  Congress office information
49  Travel information
51  Emergency procedure: The Brighton Centre
52-53  Congress social activities
54  Gala evening (Fun of the Fair)
56  ESGCT evaluation
58  European Society for Gene and Cell Therapy Achievement Awards
61  Brighton map
WELCOME ADDRESS

On behalf of the European Society of Cell and Gene Therapy and the Local Organising Committee it is my pleasure to welcome you to Brighton for the XIXth Annual Congress, which is being held this year in collaboration with the British Society for Gene Therapy.

The continued success of the annual conference mirrors the exciting developments in the field: each year we aim to offer a scientific programme that fully represents the variety of science and medicine under the joint umbrella of gene- and cell-based therapies, and we are delighted to welcome so many leading authorities to this year’s meeting. The theme for Brighton 2011 is “Letting the Science do the Talking” so you can expect a focus on cutting-edge science, translational research and the latest data from around the world. The rich and stimulating programme sees the contribution of 80 invited speakers, more than 50 selected oral presentations, and almost 400 poster presentations, and the high number of registrants is once again testimony to the quality and content of the meeting, as well as the organisation and international dimension.

With additional events for students, young scientists, industry, clinicians and principal investigators complemented by a programme of exciting social activities in a quintessentially English seaside town – famed for its stunning Royal Pavilion, elegant regency architecture, award winning restaurants and galleries – this Congress will provide a superb platform for international scientific interaction and knowledge transfer, and a unique opportunity to network with all the stakeholders in our dynamic and exciting field of research. By holding the Congress in a small, focussed area – with all hotels close to the conference centre – we are hoping to create a very friendly and interactive community feeling, perfect for building friendly relationships and collaborations. I hope that together we can continue to advance our scientific knowledge and build upon our existing excellence.

I look forward to sharing with you an outstanding and memorable scientific event. I would like to send my thanks and appreciation to all our contributors, sponsors and exhibitors, and to everyone who assisted with the Congress preparation and management, without whose commitment, enthusiasm and generosity this meeting would definitely not have been possible.

Len Seymour,  
ESGCT Congress President

COMMITTEES

Cardiovascular diseases
Andy Baker (Chair)  
Seppo Ylä-Herttuala (Chair)  
Mauro Giacca  
Moshe Flugelman  
Keith Channon  
Patrick Most

Neurological and muscular diseases
Nicole Déglon (Chair)  
Maurilio Sampaolesi (Chair)  
Nathalie Cartier-Lacave (Chair)  
Nicholas Mazarakis  
Dominic Wells  
Anders Björklund

Viral vectors
Hildegard Büning (Chair)  
Luigi Naldini (Chair)  
Rob Hoeven  
Aksel Hemminki  
Anna Salvetti  
Alberto Epstein  
Els Verhoeven

Genetic and metabolic diseases
Edvard Smith (Chair)  
Thierry VandenDriessche (Chair)  
Fatima Bosch  
Manuel Grez  
Robin Ali  
Beat Thony

Non-viral vectors
Daniel Scherman (Chair)  
Hidde Haisma (Chair)  
Ernst Wagner  
J. P. Behr  
George Dickson  
Zoltan Ivics

Infection, immune and vaccines
David Klatzmann (Chair)  
Mary Collins (Chair)  
Naomi Taylor  
Ben Berkhour  
Dorothee Von Laer  
Zelig Eshhar

Stem cells and reprogramming
Stefan Karlsson (Chair)  
Chris Baum (Chair)  
Juan Bueren  
Tim O’Brien  
Catherine Verfaillie  
Katarina Le Blanc  
Marina Radrizzani  
Willem Fibbe

Ethics and regulatory affairs
Odile Cohen-Haguenauer (Chair)  
Klaus Cichutek (Chair)  
Richard Ashcroft  
Alastair Kent  
Gösta Gahrton  
Serge Braun  
Otto Merten  
Martin Schleef  
Klaus Kühlicke  
Michael Fuchs
PROGRAMME AT A GLANCE

THURSDAY 27 OCTOBER

PUBLIC ENGAGEMENT DAY: GENE THERAPY AND STEM CELLS: 21ST CENTURY MEDICINE
Syndicate Rooms 1 and 2
Sponsors: Wellcome Trust, Fanconi Hope, CGD Trust, GSK, Blubird Bio, TAGTC

- 10.00 Registration
- 10.30 What is gene and cell therapy?
- 12.30 Hands-on activities and interactive talks
- 13.15 Lunch, meet the researchers, networking bingo, careers advice
- 14.00 Zombie Science show and conversations with an expert
- 15.00 Brain gene therapy for real
- 15.30 Interactive workshop with The Naked Scientists
- 17.00 Keynote speaker – Professor Lord Winston
- 17.15 Adjourn

EDUCATION DAY
Two parallel sessions taking place in Syndicate Rooms 3 and 4

- 13.00 1a: Strategies for delivery and expression of transgenes
  Syndicate 3
- 13.00 1b: Hot topics in gene and cell therapy and tissue engineering
  Syndicate 4
- 15.00 Afternoon break
- 15.30 2a: Immunology
  Syndicate 3
- 15.30 2b: Transgene integration
  Syndicate 4
- 17.30 Adjourn

Please note: speakers and talk titles may change

CAT-ESGCT SATELLITE WORKSHOP: ADVANCED THERAPY MEDICINAL PRODUCTS: FROM PROMISE TO REALITY
Auditorium 1
Sponsor: Bioreliance

- 08.30 Registration
- 09.15 Welcome and opening
- 09.30 Translating academic research into commercial products – regulatory considerations
  - 09.30 1: Cell-based medicinal products
- 11.00 Coffee break
- 11.30 2: Gene therapy
- 12.30 3: European and national regulatory path for ATMPs
- 13.00 Lunch
- 14.00 From regulation to reality: challenges in translation of gene therapy and cell-based medicinal products
- 14.00 4: Gene therapy – practical examples
- 15.15 Coffee break
- 15.45 5: Cell therapy and cell-based medicinal products – practical examples
- 17.00 Closing remarks
- 17.15 Adjourn

ESGCT AND BSGT CONGRESS OPENING CEREMONY
Auditorium 1

- 10.00 Registration open
- 17.30 Welcome cocktail
- 19.00 Opening symposium
- 20.30 Adjourn
# Programme at a Glance

## Friday 28 October

### Main Conference

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Location</th>
<th>Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Registration open</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30</td>
<td>Plenary session 1: Advances in clinical trials</td>
<td>Auditorium 1</td>
<td>CGD, CELL-PID</td>
</tr>
<tr>
<td>10.15</td>
<td>Morning break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.45</td>
<td>1a: Respiratory gene and cell therapy</td>
<td>Syndicate 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1b: Imaging technologies and applications</td>
<td>Syndicate 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1c: Genotoxicity #1</td>
<td>Auditorium 1</td>
<td>Clinigene, SPP1230, PERSIST</td>
</tr>
<tr>
<td>12.15</td>
<td>Lunch and poster session 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30</td>
<td>ESGCT General Assembly</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.15</td>
<td>Plenary session 2: Overcoming the hurdles to successful gene therapy</td>
<td>Auditorium 1</td>
<td>SPP1230</td>
</tr>
<tr>
<td>16.00</td>
<td>Afternoon break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>2a: Regulatory round table</td>
<td>Auditorium 1</td>
<td>Clinigene</td>
</tr>
<tr>
<td></td>
<td>2b: Careers workshop</td>
<td>Syndicate 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2c: Mechanisms of cellular differentiation</td>
<td>Syndicate 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2d: Open poster / networking session Foyer</td>
<td>Foyer</td>
<td></td>
</tr>
<tr>
<td>18.00</td>
<td>Poster party with moderated posters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00</td>
<td>Speakers' dinner by invitation only</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Saturday 29 October

### Main Conference

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Location</th>
<th>Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30</td>
<td>Themed breakfast meetings</td>
<td></td>
<td>Charles River Laboratories</td>
</tr>
<tr>
<td></td>
<td>Restaurant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td>Plenary session 3: Stem cells in health and disease</td>
<td>Auditorium 1</td>
<td>PERSIST</td>
</tr>
<tr>
<td>11.00</td>
<td>Morning break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td>3a: The Eye – cell and gene therapy</td>
<td>Syndicate 3</td>
<td>Clinigene, AAV Eye</td>
</tr>
<tr>
<td></td>
<td>3b: Cancer immunotherapy</td>
<td>Auditorium 1</td>
<td>SPP1230</td>
</tr>
<tr>
<td></td>
<td>3c: iPS cells and control of differentiation</td>
<td>Syndicate 1</td>
<td>Clinigene</td>
</tr>
<tr>
<td>13.00</td>
<td>Lunch and poster session 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00</td>
<td>Update and perspectives on European advanced therapy research</td>
<td>Auditorium 1</td>
<td></td>
</tr>
<tr>
<td>14.45</td>
<td>Plenary session 4: Cancer gene and virotherapy (ISCGT symposium)</td>
<td>Auditorium 1</td>
<td>PsiOxus, ISCGT, Jennerex</td>
</tr>
<tr>
<td>16.15</td>
<td>Afternoon break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.45</td>
<td>4a: Genetic disease</td>
<td>Syndicate 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4b: Cancer gene and virotherapy</td>
<td>Auditorium 1</td>
<td>Transgene</td>
</tr>
<tr>
<td></td>
<td>4c: Stem cells bioengineering</td>
<td>Syndicate 1</td>
<td>Hyperlab</td>
</tr>
<tr>
<td></td>
<td>4d: Non-viral technologies</td>
<td>Syndicate 4</td>
<td></td>
</tr>
<tr>
<td>18.15</td>
<td>Sussex High tea and sparkling wine with moderated posters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.00</td>
<td>Adjourn</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Please Note:** At 2am tonight the clocks will turn back one hour for the end of Daylight Saving Time.
## SUNDAY 30 OCTOBER

### MAIN CONFERENCE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Plenary session 5: Gene therapy in infectious disease</td>
<td>Auditorium 1</td>
</tr>
<tr>
<td>10.30</td>
<td>Morning break</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>5a: Manipulation of the vasculature</td>
<td>Syndicate 1</td>
</tr>
<tr>
<td></td>
<td>Sponsor: Ark</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>5b: Cell and vector manufacturing</td>
<td>Syndicate 3</td>
</tr>
<tr>
<td></td>
<td>Sponsor: Généthon</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>5c: Neuromuscular gene therapy</td>
<td>Auditorium 1</td>
</tr>
<tr>
<td></td>
<td>Sponsor: Généthon</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch and poster session 3</td>
<td></td>
</tr>
<tr>
<td>14.15</td>
<td>Plenary Session 6: Emerging technologies</td>
<td>Auditorium 1</td>
</tr>
<tr>
<td>16.00</td>
<td>Afternoon break</td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>Plenary session 7: Fairbairn Award</td>
<td>Auditorium 1</td>
</tr>
<tr>
<td>16.30</td>
<td>Sponsor: The Paterson Institute</td>
<td></td>
</tr>
</tbody>
</table>
| 17.30-19.00 | 7a: Genetic vaccines  
Syndicate 1  
Sponsor: Okairos  
7b: CNS cell and gene therapy  
Syndicate 3  
7c: New therapies  
Syndicate 4  
7d: Genotoxicity #2  
Auditorium 1 | Page 44-45 |
| 19.30 | Main congress “fun of the fair” evening including dinner, fairground games and bar |             |

## MONDAY 31 OCTOBER

### MAIN CONFERENCE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Plenary session 8: Clinical trials #2</td>
<td>Auditorium 1</td>
</tr>
<tr>
<td>10.30</td>
<td>Morning break</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>Plenary session: Presidential symposium</td>
<td>Auditorium 1</td>
</tr>
<tr>
<td></td>
<td>Outstanding Investigator Award</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Young Investigator Awards</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td>Main congress adjourns</td>
<td></td>
</tr>
</tbody>
</table>
| 13.15 | Clinigene Industry Satellite Workshop: Joint platform between industry  
and centres of excellence  
The Restaurant  
Clinigene | Page 46 |
| 16.30 | Adjourn                                                                |             |
**CLINIGENE**

Clinigene is the European network for the advancement of clinical gene transfer and therapy: FP6-EC funded network of excellence fostering interaction of all stakeholders in the field in order to facilitate and help harmonise ethical, quality, safety, efficacy and regulatory issues.

www.clinigene.eu

---

**MOLEZMED**

MolMed is a medical biotechnology company focused on research, development and clinical validation of novel antitumor therapies, with key expertise in cell and gene therapies. MolMed’s service area, GMP Solutions, provides tailor made services for the manufacturing of patient-specific or genetically modified cells and active pharmaceutical ingredients for clinical use.

www.molmed.com

---

**PERSIST**

PERSIST project explores the use of highly innovative gene-modifying and delivery technologies, and capitalises on recent discoveries in gene expression control to develop radical solutions to the problem of precisely controlling the fate and expression of exogenous genetic information in gene therapy, with applications in these and other deadly diseases. The project combines more than 20 of Europe’s outstanding experts from eight countries in the field of genetic engineering for persisting gene expression.

www.persist-project.eu

---

**BIORELIANCE**

BioReliance Corporation is a leading provider of cost-effective contract services to the pharmaceutical and biopharmaceutical industries, offering more than 1,000 tests or services related to biologics safety testing, specialised toxicology and animal health diagnostics. Our capabilities include a broad spectrum of cGMP- and GLP-compliant virological, immunological, molecular biology and microbial testing services.

www.bioreliance.com

---

**SPP1230**

SPP1230 is an interdisciplinary, multicentric Research Priority Programme of the German Research Council (DFG) with the mission to investigate ‘Mechanisms of gene vector entry and persistence’. The projects investigate basic mechanisms of cell entry, episomal maintenance or chromosomal insertion of transgenes, and the cellular and systemic responses to genetic cell modification. The overall aim of this network is to improve efficiency, predictability and biosafety of genetic therapy with a focus on hematopoietic cells.

www.schwerpunktprogramm1230.de

---

**AFM**

Created in 1958 by a group of patients and their families, and recognised as being of public utility in 1976, AFM (French Muscular Dystrophy Association) has a single objective: to defeat neuromuscular diseases, which are devastating muscle-wasting diseases. It has set itself two missions: curing neuromuscular diseases and reducing the disabilities they cause.

www.afm-france.org

---

**GÉNÉTHON**

Généthon develops and manufactures gene therapy products for rare diseases with the goal of making these innovative treatments available to patients. To meet this challenge, Généthon has assembled the technical and human resources needed to accelerate the medical application of scientific discoveries arising from fundamental research. Strong translational research programmes (at preclinical and clinical stages) engage multi-disciplinary teams and are supported by a first-rate technological platform and cGMP capacity. Généthon currently sponsors several early-phase gene therapy clinical trials (including an international trial)

www.genethon.fr

---

**TRANSGENE**

Transgene is a publicly traded French bio-pharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases, and has four compounds in advanced clinical trials. Transgene has concluded strategic agreements for the development of two of its immunotherapy products, an option agreement with Novartis for the development of TG4010 to treat various cancers, and an in-licensing agreement with US-based Jennerex Biotherapeutics Inc., to develop and market JX594/ TG6006, an oncolytic virus.Transgene has bio-manufacturing capacities for viral-based products.

www.transgene.fr
Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the design, development and commercialisation of first-in-class, targeted oncolytic products for cancer. Our lead product JX-594 is currently in two mid-stage clinical trials in patients with liver cancer. Published studies of JX-594 have shown its ability to selectively target a variety of common cancer tumor types, with improved survival and an excellent safety profile. 

www.jennerex.com

The FP7-CELL-PID European project utilises genetically modified HSC and their descendants as immunotherapeutic cells to build a healthy immune system in Primary Immuno Deficiency patients. It gathers together pioneers clinical, scientists and industrial partners in the advanced therapies field and aiming at broad clinical application of safe cell-based therapies.


SILVER PARTNERS

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. The Company has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems.

www.oxfordbiomedica.co.uk

Okairos develops genetic vaccines for major infectious diseases and cancer, using a novel proprietary technology based on new, potent, replication-incompetent Adenovirus vectors. These vectors are not neutralised by human sera, and they hold promise for generating effective T cell responses, where existing vectors have failed.

www.okairos.it

Sangamo BioSciences Inc. is developing zinc finger protein (ZFP) Therapeutics®, a new class of innovative medicines that function at the DNA level. Sangamo has ongoing clinical trials of treatments for diabetic neuropathy, HIV/AIDS, and recurrent glioblastoma multiforme. Other therapeutic programmes are focused on Parkinson’s disease, monogenic diseases and neuropathic pain.

www.sangamo.com

PsiOxus Therapeutics Ltd develops novel therapeutics for serious diseases. We are an Oxford, London and Berlin based development stage biotechnology company with world leading scientists and a highly experienced management team. Our approach is to combine different elements including small molecules, viruses, polymers and other macromolecules to produce novel patent protected therapeutics. We deliberately target diseases that result in significant associated global morbidity and mortality, with a particular focus upon cancer.

www.psioxus.com

PlasmidFactory is Europe’s leading contract manufacturer for plasmid DNA. Production ranges from the research to the industrial scale. We produce plasmids in modern laboratories with high quality standards and according to your individual wishes.

www.PlasmidFactory.com

The Hyperlab consortium gathers nine organisations – academia, research institutes and SMEs – from seven countries. Each of these partners has been carefully selected to bring particular expertise or facilities to the consortium. They share a common interest in advancing stem cell research by developing innovative technologies, and will collaborate in an integrated, synergistic approach that will lead to results that would not be achievable by any of the partners on its own.

www.hyperlab.eu

www.astrazeneca.com
Charles River is a full-service, global contract research organisation committed to delivering high-quality products and services to the pharmaceutical industry. Our broad range of capabilities spans each phase of discovery and development in every major therapeutic area, enabling you to enhance productivity and increase speed to market.

**www.criver.com**

**CANCER RESEARCH UK**

Cancer Research UK’s vision is to conquer cancer through world-class research. We are the largest volunteer supported cancer research organisation in the world and we support the work of 3,000 scientists working across the UK.

**www.cancerresearchuk.org**

**AAVEYE**

The ultimate goal of the AAVEYE consortium is to develop gene therapy strategies for the treatment of inherited severe photoreceptor diseases, namely of RP and LCA. The results of this research programme will provide the knowledge and validation to further develop novel AAV-mediated therapeutic approaches with a broad potential application in the retina and central nervous system.

**www.aaveye.eu**

**www.cgd.org.uk**

**Fanconi Hope**

Fanconi-Hope is a registered national charitable trust set up by parents of Fanconi Anaemia (FA) affected children and clinicians with an interest in FA. To support a UK Fanconi Anaemia National Registry. To promote awareness and understanding of Fanconi Anaemia among affected families, the medical profession and the general public. To encourage research in the area of Fanconi Anaemia.

**www.fanconi.org.uk**

**Tocagen**

BrainCAV is an FP7 consortium of scientists and clinicians (11 partners and 6 countries) developing tools to understand and treat brain diseases using the unique capacity of canine adenovirus (CAV-2) vectors. BrainCAV is now in its 3rd year. For more information, see www.braincav.eu or contact Dr. EJ Kremer at Institut de Génétique Moléculaire de Montpellier (eric.kremer@igm.cnrs.fr) or Dr. Anton Ottavi: +33 (0)4 72 13 89 82.

**www.braincav.eu**

**Avanti**

GlaxoSmithKline (GSK) has an established history of successfully researching and developing orphan drugs to treat rare diseases. Recognising the size of the challenge, but also the opportunity to deliver new medicines to patients, we announced the creation of a dedicated rare diseases unit in February 2010. Initially focusing on 200 rare diseases, we are collaborating with organisations and institutions to develop medicines, including gene and cell therapies, quicker and more effectively than ever before.

**www.gsk.com**

**www.liebertpub.com**
bluebird bio is developing innovative gene therapies for severe genetic disorders. The company’s proprietary platform treats genetic diseases by placing a functional gene into the patient’s extracted bone marrow stem cells, and transplanting these corrected stem cells back into the patient.

www.bluebirdbio.com

Amsterdam Molecular Therapeutics (AMT) is the world leader in gene therapy. Our first product, Glybera, is a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan genetic disorder. Glybera is filed for marketing approval with the European Medicines Agency; a decision is expected this summer. If approved, as expected, Glybera will become the first gene therapy available to patients in Europe. Subsequent filings and expected this summer. If approved, as expected, Glybera will become the first gene therapy available to patients in Europe. Subsequent filings and

www.arktherapeutics.com

Pre-order form – Public price: 95 € / Special price for ESG CT participants until 31/01/12: 80 €

First Name: ___________________________ Last Name: ___________________________
E-Mail: ________________________________________________________________
Adresse: ________________________________________________________________
City: ___________________________ Zip Code: ___________ Country: ___________
Position: ___________________________
Quantity: ___________ × 80 € = ___________ + Postage 5 € per book = Total price: ___________ = ___________ Payment by: ___________
☐ Credit Card and Fax: please return this form completed to: +33 (0)1 69 86 06 78 with:
Cardholder’s name: ___________________________ Credit card N°: ___________
Expiration date: ___________ / ___________ / ___________ Security code on the back of the credit card: ___________
☐ Check [beneficiary: EDK] and send it to: Editions EDK – Groupe EDP Sciences
17, avenue du Hoggar, P.A. de Courttabou, 91944 les Ulis cedex A, France.
To receive an invoice, please check this box: ☐ Date: ___________ Signature: ___________________________
EXHIBITORS

Booth 1: Polyplus-transfection SA develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics. Polyplus-transfection has been ISO 9001-certified since 2002 and supplies its proprietary range of reagents for the transfection of genes, oligonucleotides and siRNA through a worldwide distributor network.

www.polyplus-transfection.com

Booth 2: Caliper Life Sciences is a leading provider of in vivo imaging systems, multispectral microscopy systems and LabChip (R) technology for molecular biology. The range of systems includes the IVIS bioluminescence, fluorescence and micro CT systems which are seen as the gold standard for in vivo imaging.

www.caliperLS.com/IVIS

Booth 3: Demand Thermo Scientific products to accelerate discovery and move science forward. The Thermo Scientific portfolio includes a broad array of high-quality instruments, reagents, laboratory consumables, equipment, and services – designed to help you run your laboratory at peak performance, from start to finish. See the entire Thermo Scientific line up at

www.thermoscientific.com

Booth 4: BioOutsource is a Contract Microbiology Testing Laboratory offering an extensive range of GMP, GLP and GCP services to support safety testing and characterisation of Biologics & Vaccines. Our testing follows the guidelines provided by ICH, FDA, EMEA and various pharmacopoeias which enables BioOutsource to optimise your testing programme to comply with multiple regulatory environments.

www.biooutsource.com

www.arktherapeutics.com

Booth 5: ATMI, (Nasdaq: ATMI) is a global leader in enabling process materials and process technology for semiconductor, display and life science industries. ATMI process ingenuity unleashes new process possibilities for customers.

www.atmi-lifesciences.com
Booth 6: GenoSafe is a CSO specialised in the evaluation of the quality, efficacy and safety of gene and cell therapy products. We propose a real partnership from research stages to clinical phases. Study design, development/validation of analytical methods, and product testing; control of viral vectors batches (AAV, HIV, MLV); preclinical evaluation; clinical trial; patients' follow-up.

www.genosafe.org

Booth 7: EUFETS, a German based company, supports the development and commercialisation of cell and gene therapies. Services include cGMP-compliant manufacturing of viral vectors, genetically modified cells and, as a new service, in vitro transcribed RNA. EUFETS offers process and assay development, validation, quality control, storage and QP release. EUFETS also supports preclinical product development (R&D/GLP studies) of biologics with customised in vitro bioanalytical programmes.

www.eufets.com

Booth 8: Clinigene is the European network for the advancement of clinical gene transfer and therapy: FP6-EC funded network of excellence, fostering interaction of all stakeholders in the field in order to facilitate and help harmonise ethical, quality, safety, efficacy and regulatory issues.

www.clinigene.eu

Booth 9: BioReliance Corporation is a leading provider of cost-effective contract services to the pharmaceutical and biopharmaceutical industries, offering more than 1,000 tests or services related to biologics safety testing, specialised toxicology and animal health diagnostics. Our capabilities include a broad spectrum of cGMP- and GLP-compliant virological, immunological, molecular biology and microbiological testing services.

www.bioreliance.com

Booth 10: MolMed is a medical biotechnology company focused on research, development and clinical validation of novel antitumor therapies, with key expertise in cell and gene therapies. MolMed’s service area, GMP Solutions, provides tailor made services for the manufacturing of patient-specific or genetically modified cells and active pharmaceutical ingredients for clinical use.

www.molmed.com

Booth 12: PeproTech was established in 1988 by a group of scientists who decided to focus their efforts on the development and production of recombinant cytokines for life-science research. Today, PeproTech is a world leader in supplying high quality cytokine products including E. coli, insect, and mammalian cell-derived recombinant proteins, their monoclonal/polyclonal antibodies, ELISA development kits, and other cytokine-related reagents.

www.peprotechec.com

Booth 13: CELLON S.A. The RollerCell 40 is suitable for all current roller bottle applications in research laboratories and large scale manufacturing sites. The CELL-tainer is the next generation of disposable mixing bioreactors. The Rotary Cell Culture System is the only device that efficiently creates an environment that enables extremely fragile cell cultures and co-cultures of human and animal cell to grow into complex, sophisticated 3-D models in vitro.

www.cellon.lu

Booth 14: PlasmidFactory is Europe’s leading contract manufacturer for plasmid DNA. Production ranges from the research to the industrial scale. We produce plasmids in modern laboratories with high quality standards and according to your individual wishes.

www.plasmidfactory.com

Booth 16: Corning Life Sciences, together with our subsidiary Axygen BioScience, is a global manufacturer of tools and equipment for cell culture, molecular biology and drug screening. Products include centrifuges, liquid handling, thermal cyclers, electrophoresis, shakers, plastic cell culture consumables, purification kits and automation-friendly robotic tips.

www.corning.com

Booth 18: AgileBio specialises in scientific IT solutions for life sciences, R&D biotech and other industries. Founded in 2002, AgileBio continuously develops LabCollector, the first collaborative Intranet software for the management of lab information. LabCollector allows each scientist in the lab to manage and share their data quickly with other lab members. Built around independent modules that can interact with each other, LabCollector will manage a variety of day-to-day information like sample storage, experimental results, quality records and SOPs.

www.agilebio.com
PROGRAMME

THURSDAY 27 OCTOBER

PUBLIC ENGAGEMENT DAY: GENE THERAPY AND STEM CELLS: 21ST CENTURY MEDICINE
An interactive day for anyone who wants to find out about gene and cell therapy. Talks from experts, hands-on activities and special guests with Professor Lord Winston, The Naked Scientists and Zombie Science.
Syndicate Rooms 1 and 2

10.00 Registration

10.30 Welcome and introduction
Professor Adrian Thrasher, President of the BSGT

11.00 What is gene therapy?
Dr Maria Limberis, University of Pennsylvania

11.30 What is stem cell therapy?
Dr Tristan McKay, Queen Mary University of London

12.00 The life of a clinician doing gene therapy
Professor Iain McNeish, Cancer Research UK

12.30 DNA origami hosted by Lynda Coughlan and Co, Glasgow University
Interactive demonstration involving the audience as a method for demonstrating the complexity of DNA and how it is applied as a biomedicine

13.00 Short talk by Sense About Science and careers in science and the media

13.15 Lunch, meet the researchers, networking bingo, careers advice
A chance for attendees to quiz scientists directly about any aspect of their working lives or science

14.00 Zombie Science show
Doctor Austin
An interactive show designed to highlight gene and cell therapy in a fun and popular stage format

Sponsored by TAGTC

15.00 Brain gene therapy for real
Dr Ahad Rahim, University College London

15.30 The Naked Scientist hosts the DNA sequencing race, and the afternoon debate – scientists on the panel
School students take part in an interactive race to see who can perform DNA fingerprinting the fastest and get hands on experience of manipulating DNA. This will demonstrate how genetics, disease and treatment are important on an individual basis and how personalised medicine is becoming a reality. The audience will be able to question a panel of the speakers and other scientists and debate the ethics, practicalities, reality and possibilities presented by the novel therapies shown throughout the event.

17.00 Keynote speech
Professor Lord Winston

17.15 Adjourn
THURSDAY 27 OCTOBER

EDUCATION DAY
Syndicate Rooms 3 and 4

13.00 Parallel sessions 1a, 1b

Syndicate 3

1a: Strategies for delivery and expression of transgenes
ED01 General overview of viral/non-viral gene therapy
Len Seymour, University of Oxford
ED02 Achieving reproducible and stable transgene expression for long-term therapeutic benefit
Mike Antoniou, King’s College London
ED03 SMAR based systems
Richard Harbottle, Imperial College London

Syndicate 4

1b: Hot topics in gene and cell therapy and tissue engineering
ED04 Stem cells for studying heart disease
Chris Denning, University of Nottingham
ED05 Gene therapy for heart failure
Roger Hajjar, Mount Sinai Medical Centre, New York
ED06 Cell therapy for diabetes
Sarah Ferber, Sheba Medical Centre, Tel Aviv

15.00 Afternoon break
15.30 Parallel sessions 2a, 2b

Syndicate 3

2a: Immunology
ED07 An overview of the immune system, the challenges and opportunities it provides for gene therapy
Peter Searle, University of Birmingham
ED08 Development of therapeutic vaccines for cancer and chronic infections: from AML to HBV
Farzin Farzaneh, King’s College London
ED09 Successful engraftment and chemoselection of allogeneic HSC transduced with MGMTP140K/HSV-TK lentivirus without myeloablation or post-transplant
Karin Gaensler, University of California
ED10 Immune responses to vector and transgenes
Jim Wilson, University of Pennsylvania

Syndicate 4

2b: Transgene integration
ED10 Assessing and avoiding insertional mutagenesis
Christof von Kalle, National Centre for Tumor Diseases, Heidelberg
ED11 Manipulating insertion profiles of transposon-based vectors
Zoltan Ivics, Max Delbrück Center for Molecular Medicine, Berlin
ED12 Targeted genome engineering with designer nucleases
Toni Cathomen, Hannover Medical School

17.30 Adjourn

THURSDAY 27 OCTOBER

CAT-ESGCT SATELLITE WORKSHOP: ADVANCED THERAPY MEDICINAL PRODUCTS: FROM PROMISE TO REALITY
Auditorium 1

08.30 Registration
09.15 Welcome and opening
Seppo Ylä-Herttuala, ESGCT President
Len Seymour, Congress President
Christian K. Schneider, European Medicines Agency – CAT Chair
09.30 Translating academic research into commercial products – regulatory considerations
09.30 1: Cell-based medicinal products
Manufacturing of cell-based medicinal products: common issues and advice
Jean-Hugues Trouvin, CAT Member – France – AFSSAPS
Non-clinical development of cell-based medicinal products
Egbert Flor, CAT Member – Germany – PEI
Progressing cell-based medicinal products to market authorisation and into the clinic
Gopalan Narayanan, CAT Member – UK – MHRA
Cell-based medicinal products for a global market: FDA perspectives on common US/EU guidelines
Steven Oh, US FDA – Office of Cellular, Tissue and Gene Therapies
11.00 Coffee break
11.30 2: Gene therapy
Manufacturing of gene therapy products: common issues and advice
Maria Cristina Galli, CAT Member – Italy – ISS
Non-clinical development of gene therapy products
Beatriz Silva Lima, CAT Member – Portugal – INFRAMED
Progressing gene therapy products to market authorisation and into the clinic
Kyn Mitrophanous, Oxford Biomedica
12.30 3: European and national regulatory path for ATMPs
Role of European and national regulatory authorities: who advises on what?
Lucia D’Aposto, European Medicines Agency – CAT Scientific secretariat
MHRA speaker to be confirmed
Round table discussion: transition from an academic concept to a clinical stage – what is the regulatory path to accelerate product development?
Christian K. Schneider, European Medicines Agency – CAT Chair
THURSDAY 27 OCTOBER

13.00  Lunch

14.00  From regulation to reality – challenges in translation of gene therapy and cell-based medicinal products

14.00  4: Gene therapy – practical examples
     Gene therapy case study 1
     Gopalan Narayanan, CAT Member – UK – MHRA
     Gene therapy case study 2: ADA-SCID
     Alessandro Aiuti, HSR-Tiget, GTWP member
     Jonathan Appleby, GSK
     cGMP virus manufacture and evolving release tests
     Eleanor Berrie, Virus Manufacturing QP, University of Oxford
     Panel discussion
     Panel chairs:
     Gopalan Narayanan, CAT Member – UK – MHRA
     Maria Cristina Galli, CAT Member – Italy – ISS
     Len Seymour, ESGCT Congress President

15.15  Coffee break

15.45  5: Cell therapy and cell-based medicinal products – practical examples
     Cell-based medicinal product case study 1
     Paula Salmikangas, CAT Vice-Chair – Finland – Fimea
     Cell-based medicinal product study 2: ChondroCelect
     Wilfried Dalemans, CTO TIGENIX
     Panel discussion
     Panel chairs:
     Paula Salmikangas, CAT Vice-Chair – Finland – Fimea
     Egbert Florij, CAT Member – Germany – PEI
     Thierry VandenDriesche, ESGCT CAT member

17.00  Closing remarks
     Seppo Ylä-Herttuala, ESGCT President
     Len Seymour, Congress President
     Christian K. Schneider, European Medicines Agency – CAT Chair

17.15  Adjourn

THURSDAY 27 OCTOBER

ESGCT AND BSGT CONGRESS OPENING CEREMONY
Auditorium 1

10.00  Registration open
17.30  Welcome cocktail
19.00  Opening symposium
     Chair: Len Seymour
     The potential of genetics research
     Professor Lord Winston, Imperial College London
     Tumour viruses, rumour viruses and pseudo viruses
     Robin Weiss, University College London
20.30  Adjourn
FRIDAY 28 OCTOBER

MAIN CONFERENCE

08.00 Registration open
08.30 Plenary session 1: Clinical trials #1

Auditorium 1

<table>
<thead>
<tr>
<th>Chairs: Andy Baker, Adrian Thrasher</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INV01</strong> Gene therapy for the treatment of heart failure</td>
</tr>
<tr>
<td>Roger Hajjar, Mount Sinai Medical Centre, New York</td>
</tr>
<tr>
<td><strong>INV02</strong> Assessment of potential promoters for lentiviral gene therapy in DMD</td>
</tr>
<tr>
<td>Francesco Muntani, University College London Institute of Child Health</td>
</tr>
<tr>
<td><strong>INV03</strong> Gene therapy for immunodeficiency</td>
</tr>
<tr>
<td>Adrian Thrasher, University College London Institute of Child Health</td>
</tr>
</tbody>
</table>

Proffered papers:

| **OR01** Lentiviral vector transduced CD34+ cells for the treatment of Wiskott-Aldrich Syndrome |
| Alessandra Aiuti, Fondazione Centro San Raffaele del Monte Tabor, Milan |

10.15 Morning break

10.45 Parallel sessions 1a, 1b, 1c

Syndicate 3

| 1a: Respiratory gene and cell therapy |
| Chair: Simon Waddington |
| **INV04** Moving forward with cystic fibrosis gene therapy |
| Uta Griesenbach, Imperial College London on behalf of the UK Cystic Fibrosis Gene Therapy Consortium |
| **INV05** Cell therapy approaches for lung diseases |
| Daniel Weiss, University of Vermont College of Medicine |

Proffered papers:

| **OR02** Large-scale screening identifies coxsackievirus B3 (CVB3) as a promising oncolytic virotherapy agent against non-small cell lung cancer |
| Hiroyuki Inoue, Medical Institute of Bioregulation, Kyushu University, Fukuoka |
| **OR03** AAV9 gene transfer to the nose for pharmacologically-regulated systemic expression of therapeutic proteins |
| Maria Limbers, University of Pennsylvania |
| **OR04** Long-term follow up of pre- and postnatal pulmonary gene transfer with rAAV2/5 in a mouse model |
| Marianne Carlon, K.U. Leuven |

FRIDAY 28 OCTOBER

Syndicate 1

| 1b: Imaging technologies and applications |
| Chair: Georges Vassaux |
| **INV06** Monitoring gene therapy by non-invasive optical imaging |
| Kevin Francis, Caliper Life Sciences, Cheshire |
| **INV07** Molecular imaging of gene expression: NIS as a reporter gene |
| Georges Vassaux, Inserm U948, University of Nantes |

Proffered papers:

| **OR05** Multi-colour RGB marking to assess liver tumour development in vivo |
| Boris Fehe, University Medical Center Hamburg-Eppendorf |
| **OR06** Capsid modifications with the potential for life cycle imaging and retroviral protein transfer |
| Tobias Maetzig, Hannover Medical School |
| **OR07** Visualisation of active homing of mesenchymal stem cells into the tumor stroma of hepatocellular carcinoma (HCC) using the sodium iodide symporter as reporter gene |
| Kerstin Knoop, Ludwig-Maximilian-University Munich |

Auditorium 1

| 1c: Genotoxicity #1 |
| Chair: Chris Baum |
| **INV08** Targeting integration to selected genomic loci and in situ tailoring of cassette design allows robust transgene expression without perturbing endogenous transcription |
| Angelo Lombardo, HSR-TIGET, Milan |
| **INV09** Therapeutic strategies with integration-deficient lentiviral vectors |
| Rafael Yanez, Royal Holloway University of London |

Proffered papers:

| **OR08** Hepatic lentiviral gene transfer is associated with clonal selection, but not with tumour formation in serially transplanted mice |
| Ina Rittelmeyer, Hannover Medical School |
| **OR09** Large-scale rAAV integration site analysis in a preclinical mouse model |
| Christine Kaeppel, DKFZ/NCT, Heidelberg |
| **OR10** Lentiviral vector-based insertional mutagenesis identifies new clinically relevant cancer genes involved in the pathogenesis of hepatocellular carcinoma |
| Marco Ranzani, San Raffaele Scientific Institute, Milan |
FRIDAY 28 OCTOBER

12.15 Lunch and poster session 1

Upstairs P011-P050 CNS, respiratory and genetic and metabolic disease
Downstairs P135-P184 New delivery technologies and non-viral vectors

13.30 ESGCT General Assembly

14.15 Plenary session 2: Overcoming the hurdles to successful gene therapy
Auditorium 1 Chairs: Nathalie Cartier-Lacave, Charles Coutelle

- INV10 HSC gene therapy trial for metachromatic leukodystrophy
  Alessandra Biffi, San Raffaele Scientific Institute, Milan
- INV11 Immune responses to capsids and transgene products in pre-clinical and clinical trials
  Jim Wilson, University of Pennsylvania
- INV12 Preclinical assays to assess genotoxicity and “phenotoxicity”
  Chris Baum, Institute of Experimental Hematology, Hannover Medical School

Proffered papers

- OR11 AAV capsids induce innate immune responses in human non-parenchymal liver cells
  Hildegard Büning, University of Cologne

16.00 Afternoon break

16.30 Parallel sessions 2a, 2b, 2c, 2d

Auditorium 1

2a: Regulatory round table
Chairs: Gösta Gahrton, Alastair Kent, Nancy King
Retroviral and lentiviral vectors for long-term gene correction; clinical challenges in vector and trial design: presentation of the report on the joint RAC-Clinigene meeting in Bethesda
1. Jacqueline Corrigan-Curry, NIH-OB A RAC, Maryland
2. Dan Takefman, FDA-CBER, Maryland
First-in-human trial design and decisions: lessons from gene transfer research
Nancy M. P. King, Center for Bioethics, Health, and Society, North Carolina
The necessity for data-sharing towards advancement of clinical translation: building up sample IMPD and substantiating master files
Klaus Cichutek, Paul-Ehrlich-Institut, Langen
EMA-CAT Focus group to facilitate navigation of ATMP regulatory framework
Christian K. Schneider and Lucia d’Apote, EMA

FRIDAY 28 OCTOBER

Syndicate 1

2b: Careers workshop
Chair: Lynda Coughlan
- NV13 Advancing your research career
  Ross English, Vitae, South East Hub, UK
- NV14 An overview of scientific journals and publishing
  Jim Wilson, University of Pennsylvania
- NV15 European Research Council: supporting independent research careers
  Fiona Kernan, ERC, Brussels
- NV16 Science communication
  Julia Wilson, Sense about Science, London

Syndicate 3

2c: Mechanisms of cellular differentiation
- NV17 Using adult tissues for generating new organs: autologous cell replacement therapy for diabetes
  Sarah Ferber, Sheba Medical Centre, Tel Aviv
- NV18 Mesenchymal to epithelial transitioning enhances the reprogramming of human non pancreatic endocrine cells towards beta cells
  Kevin Docherty, University of Aberdeen

Proffered papers

- OR12 Enhanced myogenic potential of mesoangioblast-derived induced pluripotent stem cells
  Mattia Quattrocelli, K.U. Leuven

Foyer

2d: Open poster / networking session

18.00 Poster party with moderated posters
19.00 Speakers’ dinner by invitation only
### SATURDAY 29 OCTOBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30</td>
<td>Themed breakfast meetings</td>
<td>The Empress Suite, The Grand Hotel</td>
</tr>
<tr>
<td>09.00</td>
<td><strong>Plenary session 3: Stem cells in health and disease</strong></td>
<td><strong>Auditorium 1</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Chris Denning, Chiara Bonini</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INV19</strong> Human induced pluripotent stem cells for cell therapy against inherited metabolic disorders</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ludovic Vallier, University of Cambridge</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INV20</strong> Spinal cord regeneration using ES cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jane Lebkowski, Geron Corporation, California</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INV21</strong> Cancer stem cells: a source of new therapeutic targets?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Norman Maitland, University of York</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INV22</strong> Exploring and exploiting TALE nucleases (TALENs) for targeted genome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Toni Cathomen, Hannover Medical School</td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td>Morning break</td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td><strong>Parallel sessions 3a, 3b, 3c</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Syndicate 3</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>3a: The Eye – cell and gene therapy</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Robin Ali</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INV23</strong> Development of stem cell therapy for the treatment of retinal degeneration</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robin Ali, University College London Institute of Ophthalmology</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INV24</strong> Utilisation of IPS cells for retinal degenerative diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Masayo Takahashi, RIKEN, Kobe</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INV25</strong> Challenges and successes of retinal gene therapy with AAV vectors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alberto Auricchio, The Telethon Institute of Genetics and Medicine (TIGEM) and Federico II University, Naples</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Proffered papers</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>OR13</strong> Gene replacement therapy in mouse models of inherited cone photoreceptor disorders</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alexander Smith, University College London</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>OR14</strong> AAV8-mediated expression of VEGF antagonists in macaque eye: comparison of subretinal vs. intravitreal delivery of vector</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maria Limbers, University of Pennsylvania</td>
<td></td>
</tr>
</tbody>
</table>

### PLEASE NOTE:
At 2am tonight the clocks will turn back one hour for the end of Daylight Saving Time.
SATURDAY 29 OCTOBER

13.00
Lunch and poster session 2
Upstairs
P051-P089 Stem cell bioengineering, Genotoxicity/targeted integration and neuro and muscle
Downstairs
P185-P235 Viral vectors

14.00
Auditorium 1
Update and perspectives on European advanced therapy research
David Gangbe, European Commission Research and Innovation Directorate General, Brussels

14.45
Plenary session 4: Cancer gene and virotherapy (ISCGT symposium)

Auditorium 1
Chairs: Farzin Farzaneh, Nori Kasahara

INV30 Demonstration of safety and antitumoral activity of JX-594, a targeted multi-mechanistic oncolytic poxvirus, following intravenous infusion and/or intratumoral injections in patients with refractory metastatic cancers
David Kim, Jennerex Inc., San Francisco
Sponsored by ISCGT

INV31 Virotherapy in the UK
Kevin Harrington, Institute for Cancer Research, London

INV32 Molecular design of improved adenoviruses
Ramon Alemany, Catalan Institute of Oncology-IDIBELL, Barcelona

16.15
Afternoon break

16.45
Parallel sessions 4a, 4b, 4c, 4d

Syndicate 3
Chairs: Steve Howe, Suzi Buckley

INV33 Fetal and neonatal gene therapy
Simon Waddington, University College London

INV34 Zooming in on the target: transductional and transcriptional targeting
Thierry VandenDriessche, V. U. Brussels

Proffered papers

OR21 Inflammation converts immunologically inert human mesoangioblasts into sensitizers and targets of the alloreactive response: implications for allogeneic cell therapy of DMD
Maddalena Noviello, The San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET)

OR22 Development of a new strategy for X-CGD gene therapy using a miRNA regulated lentiviral vector
Giada Farinelli, Children’s hospital Bambino Gesù and Tor Vergata University, Rome

OR23 AAV mediated Factor VIII expression from a novel expression cassette with a potent codon-optimised FVIII construct
Jenny McIntosh, University College London

Syndicate 1
Chairs: Heiko Zimmermann, Paula Alves

INV35 Targeting DNA damage repair and paclitaxel resistance in ovarian cancer using oncolytic adenoviruses
Iain McNeish, Barts Cancer Institute, Queen Mary University of London

INV36 An ascending dose phase 1 trial of the safety and tolerability of Toca 511 in subjects with recurrent high grade glioma
Doug Jolly, Tocagen Inc., San Diego

Proffered papers

OR24 Human data with a desmoglein 2 binding oncolytic adenovirus Ad3-hTERT-E1A
Otto Hemminki, University of Helsinki

OR25 Enhancement of antitumour efficacy of E3B-deleted oncolytic adenoviruses by targeting STAT1 that interacts with E3 14.7 protein of adenovirus in macrophage
Yaohe Wang, Barts Cancer Institute, Queen Mary University of London

OR26 Adenovirus with hexon Tat-PTD modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors
Di Yu, Rudbeck Lab KlinimmI(KGP), Uppsala

Invited speakers

14b: Cancer gene and virotherapy
Chairs: Iain McNeish, Len Seymour

INV35 Targeting DNA damage repair and paclitaxel resistance in ovarian cancer using oncolytic adenoviruses
Iain McNeish, Barts Cancer Institute, Queen Mary University of London

INV36 An ascending dose phase 1 trial of the safety and tolerability of Toca 511 in subjects with recurrent high grade glioma
Doug Jolly, Tocagen Inc., San Diego

Proffered papers

OR24 Human data with a desmoglein 2 binding oncolytic adenovirus Ad3-hTERT-E1A
Otto Hemminki, University of Helsinki

OR25 Enhancement of antitumour efficacy of E3B-deleted oncolytic adenoviruses by targeting STAT1 that interacts with E3 14.7 protein of adenovirus in macrophage
Yaohe Wang, Barts Cancer Institute, Queen Mary University of London

OR26 Adenovirus with hexon Tat-PTD modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors
Di Yu, Rudbeck Lab KlinimmI(KGP), Uppsala
SATURDAY 29 OCTOBER

Syndicate 4 4d: Non-viral technologies
Chairs: Hidde Haisma, Matthew Wood
INV39 Endosomal escape pathways for delivery of biologicals
          Hidde Haisma, Groningen Research Institute of Pharmacy, Groningen University
INV40 Exosome-mediated RNAi delivery for neurological disease
          Matthew Wood, University of Oxford
Proffered papers
OR29 Replicating minicircles: Overcoming the limitations of transient and stable expression systems
          Juergen Bode, Hannover Medical School (MHH)
OR31 Development of minicircle-DNA vectors as non-viral liver-directed gene therapy for phenylketonuria (PKU)
          Hiu Man Viecelli, University of Zurich
OR32 Orally administered chitosan nanoparticles for gene delivery of FIX to treat hemophilia B
          Patricia Quade-Lysy, DRK-Blutspendedienst Baden-Württemberg, Hessen

18.15 Sussex high tea and sparkling wine with moderated posters
20.00 Adjourn

SUNDAY 30 OCTOBER

09.00 Plenary session 5: Gene therapy in infectious disease
Auditorium 1 Chairs: Uta Griesenbach, Mary Collins
INV41 ZFN-edited CD4 T cells for HIV/AIDS Therapy: Phase 1 trials to evaluate the safety and tolerability of SB-728-T in HIV-infected subjects
          Phil Gregory, Sangamo BioSciences, California
INV42 Genetic vaccines for malaria
          Adrian Hill, University of Oxford
INV43 Restriction factors and gene therapy for HIV
          Greg Towers, University College London

10.30 Morning break
11.00 Parallel sessions 5a, 5b, 5c
Syndicate 1 5a: Manipulation of the vasculature
Chair: Stuart Nicklin
INV44 microRNAs in post-ischemic angiogenesis
          Costanza Emanuelli, Laboratory of Vascular Pathology and Regeneration, School of Clinical Sciences, University of Bristol
INV45 Gene therapy of familial hypercholesterolemia
          Seppo Ylä-Herttuala, A. I. Virtanen Institute; University of Eastern Finland
Proffered papers
OR32 Hypoxia-regulated HO-1 expression improves post-ischemic blood flow and skeletal muscle regeneration
          Agnieszka Jazwa, Jagiellonian University, Krakow
OR33 Reducing LDL cholesterol with exon-skipping antisense oligonucleotides
          Petra Disterer, University College London
OR34 Role of antioxidants genes in angiogenesis: significance for endothelial progenitor cells
          Jozef Dulak, Jagiellonian University, Krakow

18.15 Sussex high tea and sparkling wine with moderated posters
20.00 Adjourn
### SUNDAY 30 OCTOBER

#### Syndicate 3

**5b: Cell and vector manufacturing**

**Chair:** Olivier Danos  
**INV46** Purification and analysis of virus, VLP and pDNA vectors for gene therapy with CIM® monolith chromatography  
John Creedy, Progressive Research Systems Ltd on behalf of BIA Separations GmbH  
**INV47** Manufacture of clinical-grade lentiviral vectors for ex vivo use  
Anne Galy, Généthon, Paris

**Proffered papers**

**OR37** Improved manufacturing of measles virus for human oncolytic virotherapy clinical trials  
Mark Federspiel, Mayo Clinic, Minnesota

#### Auditorium 1

**5c: Neuromuscular gene therapy**

**Chair:** George Dickson  
**INV45** Systemic AAV9 gene therapy of spinal muscular atrophy  
Martine Barkats, Inserm, Institut de Myologie, Paris  
**INV50** Genetic therapies for duchenne muscular dystrophy  
George Dickson, Royal Holloway University of London  
**INV51** Effective limb transduction and phenotypic correction after injection of rAAV8-U7snRNA in GRMD dogs  
Philippe Moullier, Généthon, Paris

**Proffered papers**

**OR36** Tau reprogramming by RNA trans-splicing: a gene therapy strategy for neurodegenerative diseases  
Maria-Elena Avale, King’s College London

12.30 **Lunch and poster session 3**

**Upstairs**

P090-P134 Stem cells and reprogramming, ocular disease, manufacture, regulatory and ethics, immunological and vaccines and imaging

**Downstairs**

P236-P290 Cancer/Vaccines/virotherapy, cardiovascular disease and late breaking news

#### SUNDAY 30 OCTOBER

14.15 **Plenary Session 6 : Emerging technologies**

**Auditorium 1**

**Chairs:** Luigi Naldini, Christof von Kalle  
**INV52** Cellular Recognition and Restriction of Viruses and Vectors  
Matthew Weitzman, The Children’s Hospital of Philadelphia  
**INV53** Correction of factor IX gene  
Kathy High, Howard Hughes Medical Institute and The Children’s Hospital of Philadelphia  
**INV54** Target site selection of transposon-based vectors and strategies for targeted transgene insertion  
Zoltan Ivics, Max Delbrück Center for Molecular Medicine, Berlin

**Proffered papers**

**OR37** Alpharetroviral SIN vectors: Favorable integration characteristics in murine hematopoietic stem cells and decreased genotoxicity in the In Vitro Immortalization Assay  
Julia Debora Suerth, Hannover Medical School

16.00 **Afternoon break**

16.30 **Plenary session 7: Fairbairn Award**

**Auditorium 1**

**Proffered papers**

**OR38** Genetic modification of cancer cells using non-viral, episomal S/MAR vectors for in vivo tumour modeling  
Suet Ping Wong, Imperial College London  
**OR39** A novel gene- and drug-based combined intervention for stroke is neuroprotective in vitro and in vivo  
Emily Ord, University of Glasgow  
**OR40** A cluster of basic amino acids in the factor X serine protease mediate surface attachment of adenovirus/FX complexes  
Margaret Duffy, University of Glasgow  
**OR41** Sheep amniotic fluid derived CD34+ stem cells engraft in NOD-SCID gamma mice and in lambs after prenatal autologous transplantation  
S. W. Steven Shaw, University College London
<table>
<thead>
<tr>
<th>Time</th>
<th>Sessions</th>
<th>Details</th>
</tr>
</thead>
</table>
| 17:30-19:00  | Parallel sessions 7a, 7b, 7c, 7d | **Syndicate 1**  
**7a: Genetic vaccines**  
*Chair: Kerry Fisher*  
**INV55** Novel chimpanzee adenovirus vector vaccines inducing adaptive cellular immunity  
*Alfredo Nicosia, Okaired, Rome*  
**INV56** Pre-immune models for improved vaccine design  
*Kerry Fisher, University of Oxford*  
*Proffered papers*  
**OR42** T cells expressing genetically modified CD8 co-receptor have enhanced T cell effector function  
*Emma Morris, University College London*  
**OR43** Antigen-expressing immunostimulatory liposomes: a novel genetically-programmable vaccine platform  
*Enrico Mastrobattista, Utrecht University*  
**OR44** Improved systems for generating and evaluating adenovirus vaccine vectors reveal differences in immunogenicity between vectors of different adenoviral species  
*Matthew Dicks, University of Oxford*  
|
| 19.30        | Main congress “fun of the fair” evening including dinner, fairground games and bar | **Syndicate 4**  
**7c: New therapies**  
*Chair: Mark Tangney*  
**NV60** Engineering bacteria for simultaneous imaging and therapy of cancer  
*Jung-Joon Min, Chonnam National University, Hwasun Hospital, South Korea*  
**NV61** Tumour-specific bacterial growth: a vector toolbox for localising cancer therapeutics  
*Mark Tangney, Cork Cancer Research Centre, University College Cork*  
*Proffered papers*  
**OR47** A new lentiviral vector pseudotype outperforms by far VSV-G-LVs for gene transfer into hematopoietic stem cells  
*Elis Verhoyen, Inserm, University of Lyon*  
**OR48** Ultrasound-enhanced delivery of polymer-coated oncolytic adenovirus for tumour growth inhibition  
*Robert Carlisle, University of Oxford*  
|
| **SUNDAY 30 OCTOBER** | **Auditorium 1**  
**7d: Genotoxicity #2**  
*Proffered papers*  
**OR46** Defining the lentiviral integrome in human hematopoietic cells  
*Alessandra Recchia, University of Modena e Reggio Emilia*  
**OR50** Tracking hematopoietic stem cell fate in humans by retroviral tagging  
*Luca Biasca, The San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET)*  
**OR51** Lentiviral vector common integration sites in the ALD and MLD clinical trials and in a preclinical model reflect a benign integration bias and not oncogenic selection  
*Eugenio Montini, The San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET)*  
**OR52** Read-through/splicing-capture mechanism is the major determinant of enhancer genotoxicity of vectors with active LTRs  
*Daniela Cesana, HSR-TIGET, Milan*  
|
MONDAY 31 OCTOBER

09.00  Plenary session 8: Clinical trials #2
Auditorium 1

Chair: Thierry VandenDriessche, Rafael Yanez

ProSavin® a gene therapy approach for the treatment of parkinson's disease: phase I clinical trial update
Stéphane Palfi, CEA-CNRS MirCen, France and Oxford BioMedica

OncoVEX GM-CSF: from bench, to bedside; to approved drug
Robert Coffin, Biovex, Massachusetts

A Phase I/II clinical trial entailing peripheral vein administration of a novel self-complementary adeno-associated viral vector encoding human FIX for Haemophilia B gene therapy
Amit Nathwani, University College London

10.30  Morning break

11.00  Plenary session 9: Presidential symposium
Auditorium 1

Chair: Seppo Ylä Hertuala

Presidential Talk
Seppo Ylä Hertuala, A. I. Virtanen Institute, University of Eastern Finland

Outstanding Achievement Award
Adrian Thrasher, University College London Institute of Child Health

Young Investigator Awards

OR52  “Factor-free” murine induced pluripotent stem cells for monogenetic neutrophil disease models
Axel Schambach, Medical School Hannover

OR53  Genome-wide analysis of zinc finger nuclease specificity
Richard Gabriel, NCT Heidelberg

OR54  Developing safer gene therapy approaches by zinc finger nucleases-mediated gene editing
Angelo Lombardo, HSR-TIGET, Milan

OR55  A Hematopoietic Stem Cell (HSC) specific microRNA renews gene therapy and gives novel insights into the regulation of HSC homeostasis
Bernhard Gentner, The San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET)

12.30  Main congress adjourns

13.15  Clinigene Industry Satellite Workshop

The Restaurant

Joint platform between industry and centres of excellence

16.30  Adjourn

---

**Clinigene Industry Satellite: Joint Platform Between Industry & Centres of Excellence - 5th Edition**

Monday October 31st 2011, Brighton (UK) 13.15 - 16.00

Industry-Academic centres of excellence collaboration in challenges for early-phase clinical trials

**Chairmen:** Martin Wisher (BioReliance, UK) & Manuel Carrondo (IBET, PT)

13.15 Finger buffet

13.30  - Introductions
by Martin Wisher (Chair of the Clinigene Industry Committee) & Manuel Carrondo 5'

13.35  - Presentations

- “The benefits and pitfalls of R&D collaborations with industry”
  Kerry Fisher (PsiOxus, UK) 10+5'

- “Gene therapy development for orphan diseases requires more academics than trial subjects - illustration from the Glybera for LPLD case”
  Janneke de Wal (AMT, NL) 10+5'

- “Merging Ad5 academic products and validated production processes”
  Robert Shaw (Ark Therapeutics, FI-UK) 10+5'

- “An accessible academic translational infrastructure: our role and challenges after 10 years”
  Larry Couture (Beckman Research Institute of City of Hope, USA) 10+5'

- “It takes a whole village to raise a child: Taking SB-728-T from concept to clinic”
  Philip Gregory (Sangamo, USA) 10+5'

- Title pending
  Gabor Veres (BlueBird Bio, USA-FR) 10+5'

- “Innovation is where you find it - one size does not fit all”
  Sam Wadsworth (Genzyme R&D Center, part of Sanofi Group) 10+5'

15.20  - Round Table
chaired by Alan Boyd (Alan Boyd Consultants, UK), Felicia Rosenthal (CellGenix, DE) & Jeffrey Ostrove (CereGene, USA):

- How do Academia & Industry collaborate with each other, and on which ground it is maintained,
- What are the main difficulties and successes,
- What are the bottlenecks (research, intellectual property, timelines, management, regulatory issues…),
- Suggestions to improve these kind of collaborations in the future, and based on past experience.

15.55  - Meeting Wrap-up
CONGRESS OFFICE INFORMATION

Contact names
Clare Beach – Administration Manager
Renée Watson – Business Manager

Registration desk opening hours
Thursday 27 October 08.00-20.00
Friday 28 October 07.45-19.00
Saturday 29 October 08.00-15.00
Sunday 30 October 08.30-19.30
Monday 31 October 08.30-13.30

For information on BSGT and local attractions, please go to the BSGT and Visit Brighton information points, which will be located in the foyer and will be open from 10.00-16.30

Payment queries
Please go to the registration desk during the above opening hours

Membership queries
Please go to the registration desk during the above opening hours

Contact number in case of emergency
Renée Watson, ESGCT Business Manager, +44 7903 233064

TRAVEL INFORMATION

Conference venue
The Brighton Centre
Kings Road, Brighton, East Sussex, BN1 2GR
Tel: 01273 290131
Fax: 01273 779980
www.brightoncentre.co.uk

Getting around in Brighton
Walking is one of the best ways to discover the city. People sometimes forget that Brighton is rich in heritage and simply bursting with stunning Regency architecture. Combine this with a compact, walkable city and you’ve got the perfect place for a walking tour.

You can download excellent walking maps and information from:
www.visitbrighton.com/site/maps-guides-and-interactive/maps

The ‘Flavour of the Lanes’ walking tour gives a great taste of all that you should see, and is possible to do in chunks of time across the week:
www.visitbrighton.com/site/maps-guides-and-interactive/walking-tours

LOCAL TAXIS
The main city centre taxi ranks are in East Street, Queen’s Square and at the Rail Station.
Brighton and Hove Radio Cabs: 01273 204060
City Cabs: 01273 205205
Streamline Taxis: 01273 202020 / 747474

LOCAL BUSES
Brighton and Hove Buses cover all areas of the city centre and beyond. ‘CitySAVER’ tickets offer unlimited travel on virtually all bus services in the city. If you wish to combine both train and bus travel, just ask for a ‘Plusbus’ ticket when buying your train ticket.
Increasing numbers of Gene Therapy studies report on therapeutic efficacy, in particular for the treatment of rare monogenetic diseases. However, the broader use of Gene Therapy concepts is currently precluded by the occurrence of adverse events. Understanding the basic mechanisms of vector-mediated gene delivery and cell modification will be key to improving the safety and also efficacy of Gene Therapy.

The Research Priority Program 1230 “Mechanisms of Gene Vector Entry and Persistence” of the German Research Council (DFG) was initiated in 2006 to address these core questions. Specifically, projects in the “Area Vector Fate” investigate aspects of early interaction between vectors and their target cells, such as vector entry, episomal persistence or chromosomal insertion of transgenes, while projects of the “Area Cell Fate” focus on deciphering the factors that determine the fate of gene-modified cells in the organism.

To comprehensively tackle these core research topics, projects belonging to the fields of virology, cell biology, haematology, bioinformatics and mathematical modelling were selected by an international board of reviewers. Coherence and timeliness of this multidisciplinary research consortium is further ensured by extensive internal and external networking, and through organisation and support of national and international congresses.

For further information on the Research Priority Program SPP1230 visit www.schwerpunktprogramm1230.de

---

**EMERGENCY PROCEDURE: THE BRIGHTON CENTRE**

1. **UPON HEARING THE ALARM (INTERMITTENT)**
   a) The alarm will be silenced whilst the activated area is checked.
   b) Standby and await further information.

2. **UPON HEARING THE ALARM (CONTINUOUS RINGING)**
   a) LEAVE THE BUILDING by the nearest available exit – follow all instructions given by Brighton Centre Staff and Duty Manager.
   b) DO NOT wait to collect personal belongings (e.g. coats, handbags) and DO NOT wait around for others. DO NOT USE THE LIFTS.
   c) DO NOT run or panic – there is no need. Move swiftly but calmly.
   d) CLOSE THE DOOR if you are the last to leave the room you are in.
   e) PROCEED to the assembly point at the junction of RUSSELL ROAD/WEST STREET at the rear of the building.
   f) WAIT at the assembly point for further instruction from Brighton Centre staff.
   g) DO NOT RE-ENTER THE BUILDING without permission.

3. **IF YOU SHOULD DISCOVER A FIRE (AND NO ALARM HAS YET BEEN SOUNDED)**
   a) OPERATE THE ALARM from the nearest alarm point.
   b) Proceed as per point 2 above.
CONGRESS SOCIAL ACTIVITIES

Some of the greatest ideas come from discussions over a pint! In many ways the social activities can make the congress a real experience so we have incorporated the best of Britain and Brighton in the following social activities:

Whole Congress “Fun of the Fair” Gala evening
Sunday 30 October, 19.30, Hilton Brighton Metropole Hotel (see page 54 for details).

Morning jog, bicycling and sea kayaking
If you fancy swapping your lab coat for a pair of trainers, then Sunday morning will give you a chance to test yourself against your fellow delegates in a morning jog along the beach. If you aren’t so keen on running but still want to get out on the beach there will be sea kayaks or bicycles available for you to have a try of with the help of some local experts to show you how it’s done.

BIKE RENTAL
Brighton Sports Company is pleased to provide a bike rental service for our Congress delegates on Brighton and Hove seafront. The service adds a new dimension to the services on offer in one of the busiest beach resorts in the UK. Located right next to the coastal bike path on Madeira Drive, Brighton, it is the perfect location to see the best of what Brighton and Hove has to offer.

**Opening hours:**
- 07.00-09.00 – Pre booking only.
- 10.00-18.00 – Open bookings and turn up and ride subject to availability.
- 18.00-19.00 – Pre booking only

- 1 hour: £5 (normally £6)
- 2 hours: £8 (normally £9)
- 3 hours: £10 (normally £12)
- 4 hours plus: £14 (normally £16)

Bookings can be made by email mark@brightonsports.co.uk or by phone 07917 753794

Payment: cash only. Delegates will need to show conference ID to claim discounted rates.

Maps and advice on where to cycle are available with all bookings. All bikes come with locks and helmets if required.

KAYAKING
Head on down to Brighton Watersports and experience Brighton in a way most others don’t! See Brighton’s West Pier up close from the far side; get that freedom of being out on the open waves without exerting the energy required by swimming; open your eyes to a new view of Brighton! We offer anything from kayaking, stand up paddle boarding, wakeboarding, water-skiing, ringo’s and more!

**Session times:**
- 07.30-09.30
- 12.00-14.00
- 17.00-18.30

Sessions last 40 minutes and the first 100 people to book will get their session for free! You must **quote the congress** when you book and **show your delegate badge** when you arrive to get this offer.

Bookings can be made by phone on 01273 323160 (we will need 12 hours’ notice to secure your kit)

How to find us: we are situated on the seafront, down on the beach itself, half way between the palace and West Pier, in front of the Old Ship Hotel.

Contact details:
The Brighton Watersports, 185 Kings Road Arches, Brighton Seafront, BN1 1NB
info@thebrightonwatersports.co.uk

**Poster party and English afternoon tea**
If there is one thing the English do well it is scones and tea! We couldn’t think of a better marriage than high quality scientific discussion of posters with an English Afternoon Tea. This is a great chance to get to chat with our exhibitors as well whose products can make a big difference to your work.

**Good food, yes in England!**
We will be doing our best to bust those myths about English food by investing in a really delicious menu for the congress. We will be having bowl food most days which offers a selection of nutritious, hot meals and desserts including plenty of options for vegetarians. In addition there will be free coffee, tea, water and fruit available throughout the day to keep you going.
Fun of the Fair

Sunday 30 October 2011
Hilton Brighton Metropole Hotel
19.30

All congress participants are invited to a night of fun, food and festivities, at a subsidised price of €30 (payable at the registration desk).

We will be bringing all the fun of Brighton Pier inside our hotel with ice cream, funfair stalls such as hoopla, coconut shy, cork rifle game and tin can alley, and giant scalextrics. There will be a full bar all washed down with a healthy portion of fish ‘n chips.

Please make your way to Hilton Brighton Metropole Hotel (see map opposite) at 19.30 and follow the signs to The ESGCT/BSGT Fun of the Fair evening.

If you haven’t already registered for this event on our website please come to the registration desk.

Your first two drinks FREE!

GENE THERAPY TREATMENTS FOR RARE DISEASES
From research to treatments for patients
Created in 1990 by AFM (the Association Française contre les Myopathies) and funded by the donations of the French Telethon.

FOR MORE INFORMATION and details: www.genethon.fr
ESGCT EVALUATION

We do hope you have enjoyed the ESGCT/BSGT Collaborative Congress 2011. We really value your feedback about all aspects of the Congress. We would be very grateful if you could take a few minutes to complete this online questionnaire either during or soon after the Congress. There are several workstations with internet access available by the registration desk that you can use to complete the survey:

www.surveymonkey.com/s/LQBDSWN

A link is also available from the ESGCT website.

If you enjoyed this meeting, would you consider hosting/organising an ESGCT or BSGT congress in 2014? If so, please forward your proposal to the ESGCT Board as soon as possible at office@esgct.eu, or the BSGT Board at office@bsgt.org.

Thank you in advance for your time.

ESGCT and BSGT Team

BSGT ANNUAL CONFERENCE, LONDON 2012

Unique opportunities for young scientists to:
- shape the programme
- chair sessions
- present data

Save the date!

Friday 9 March 2012

University College London Institute of Child Health

www.bsgt.org

If you’ve enjoyed the conference why not book your next meeting or event in Brighton & Hove?

The VisitBrighton Convention Bureau are your resident experts and can help you to-
- Find the right venue
- Source, negotiate and book accommodation via our free accommodation booking service
- Organise a familiarisation visit
- Give you ideas for your social programme
- Provide high quality films, images and maps for your website, brochure and delegate packs

Contact us now:
01273 292629
conferences@visitbrighton.com
www.visitbrighton.com/conferences
www.fb.com/LoveBrightonBusinessBuddies
http://linkdin.com/peertopier
A New Treatment Approach Under Investigation for Recurrent High Grade Glioma

CURRENTLY ENROLLING: TOCA 511 & 5-FC IN MULTICENTER, ASCENDING-DOSE STUDIES IN PATIENTS WITH RECURRENT HGG

KEY ENTRY CRITERIA:
• Prior surgery, RT, and TMZ
• Age 18 and over

For more information, including a listing of study site locations, please visit www.tocagen.com/clinicalstudies or visit www.clinicaltrials.gov and search for Toca 511

Toca 511 is an investigational product. An investigational product is one that has not been proven to be safe and effective for this use and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.

EUROPEAN SOCIETY FOR GENE AND CELL THERAPY ACHIEVEMENT AWARDS

Outstanding Achievement Award: one award for an established researcher who has made a long term, outstanding contribution to the field.

Young Investigator Awards: €1000 and a guest speaker invitation for up to four researchers (max age 40) who are showing exceptional promise.

Best Abstract Award: €500 for the top two abstracts.

Travel grants: up to 10 awards of €250 for PhD and first post docs. These will be awarded on the basis of abstract score.

Application and nomination forms are available at www.esgct.eu/awards
ESGCT 20th Anniversary Congress
in collaboration with the SFTCG

26-29 October 2012

European Society of Gene and Cell Therapy
and
French Society of Cell and Gene Therapy

Will Hold a Joint Meeting in Versailles

www.esgct.eu • www.sftcg.fr